Group 1 - The Hong Kong Stock Connect innovative drug sector is experiencing a significant rally, with Ascentage Pharma-B leading with a nearly 6% increase, and several other stocks like Kelun-B and 3SBio rebounding over 4% [1] - The Hong Kong Stock Connect Innovative Drug ETF (520880) is fully invested in innovative drug R&D companies and saw a trading increase of up to 2% in the afternoon session, with a transaction volume exceeding 340 million yuan [1] - The ETF has attracted over 129 million yuan in net subscriptions during recent dips, indicating strong buying interest [1] Group 2 - The ESMO 2025 annual meeting will take place from October 17-21 in Berlin, where multiple Chinese innovative drug companies are expected to announce breakthrough clinical research results in areas such as kidney and lung cancer [3] - The Federal Reserve's dovish stance suggests a potential interest rate cut in October, which may create a favorable environment for the Chinese pharmaceutical sector [3] - Recent BD transactions, such as the one involving Innovent Biologics with a total value exceeding 2 billion USD, indicate a busy end-of-year period for global innovative drug product licensing collaborations [3] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) is the first ETF tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which exclusively focuses on innovative drug companies without including CXO [4] - As of the end of September, the fund size of the ETF is 1.806 billion yuan, with an average daily trading volume of 493 million yuan, making it the largest and most liquid ETF in its category [4] - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has shown a year-to-date increase of 108.14%, outperforming other innovative drug indices [6]

Core Viewpoint - The Hong Kong innovative drug sector has rebounded after a period of adjustment, with the Hang Seng Innovative Drug Index rising by 2.0% as of 14:00, indicating renewed investor interest in this segment [1]. Group 1: Market Performance - The Hang Seng Innovative Drug Index saw significant gains, with stocks such as Ascentage Pharma-B rising over 5%, and both 3SBio and Tonghua Dongbao Pharmaceutical-B increasing by more than 4% [1]. - The Hang Seng Innovative Drug ETF (159316) has experienced a net inflow of approximately 400 million yuan over the past five trading days, reflecting positive market sentiment [1]. Group 2: Upcoming Events - The 2025 European Society for Medical Oncology (ESMO) annual meeting is scheduled to take place from October 17 to October 21 in Berlin, Germany, which is expected to showcase several significant clinical research results, potentially boosting market interest in innovative drug assets [1]. Group 3: Index Composition - The Hang Seng Innovative Drug Index has excluded CXO companies in its compilation scheme, making it the first index with a "100% purity" focus on innovative drugs, accurately reflecting the overall performance of China's innovative pharmaceutical companies [1]. - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index, providing investors with a precise opportunity to capitalize on the development of the innovative drug industry [1].

来源：新浪基金 10月15日，港股通创新药板块终于反弹，核心标的"520880"溢价涨逾1%，实时成交超2.9亿元。成份股 方面，同源康医药-B、亚盛医药-B强势领涨，权重股三生制药涨超3%。 华福证券指出，创新药板块短期受市场情绪影响调整，但产业趋势未改。创新药三季报预期较好，10月 ESMO等会议或带来超预期数据催化，叠加Q4潜在BD落地，或迎第二波行情 国金证券也指出，创新药产业向上趋势不变，年底全球创新药产品授权合作密集，板块行情静待BD持 续催化。ESMO大会即将召开，关注国内药企重磅临床数据。 港股通创新药ETF（520880）及其联接基金（联接A：025220，联接C：025221）被动跟踪恒生港股通 创新药精选指数，该指数前十大权重股分别为百济神州、中国生物制药、信达生物、康方生物、石药集 团、三生制药、翰森制药、科伦博泰生物-B、再鼎医药、诺诚健华。 数据来源于沪深交易所、公开资料等。 风险提示：以上产品由基金管理人发行与管理，代销机构不承担产品的投资、兑付和风险管理责任。投 资人应当认真阅读《基金合同》、《招募说明书》、《基金产品资料概要》等基金法律文件，了解基金 的风险收益特征，选择与自 ...

Core Viewpoint - Hong Kong stocks opened higher with the Hang Seng Technology Index rising over 1%, driven by gains in tech and innovative pharmaceutical sectors [1] Group 1: Market Performance - The Hang Seng Technology Index increased by more than 1%, with notable gains in JD Health and Bilibili, both rising over 4%, and Alibaba Health and Alibaba rising over 3% [1] - The Hang Seng Pharmaceutical ETF and Hong Kong Stock Connect Technology ETF both saw increases of over 1% [1] Group 2: Economic Indicators - Federal Reserve Chairman Jerome Powell warned of further challenges in the U.S. labor market, suggesting a potential interest rate cut before the October monetary policy meeting [1] Group 3: New Financial Products - Hong Kong Stock Exchange announced plans to launch the Hang Seng Biotechnology Index futures, set to begin trading on November 28, 2025, aimed at providing precise risk management tools for investors [1] Group 4: Fund Flows - Despite a cumulative decline of over 9% in the Hong Kong Stock Connect Technology ETF from October 9 to October 14, there was a net inflow of 270 million yuan during this period [1] - The Hang Seng Pharmaceutical ETF experienced a decline of over 10% but still attracted a net subscription of 175 million yuan [1] - The defensive Hong Kong Central Enterprise Dividend ETF received a net inflow of 279 million yuan amid renewed focus on dividend strategies [1] Group 5: Notable Products - The Hang Seng Pharmaceutical ETF (159892) rose by 1.04%, with top-weighted stocks including innovative pharmaceutical companies like BeiGene and WuXi Biologics [2] - The Hong Kong Stock Connect Technology ETF (159101) increased by 1.01%, with over 60% exposure to major tech firms like Alibaba and Tencent, and a special focus on innovative drugs [2] - The Hong Kong Central Enterprise Dividend ETF (513910) rose by 0.88%, including major stocks such as COSCO Shipping and China Petroleum [2]

Core Viewpoint - The Hong Kong pharmaceutical sector experienced a rapid surge, led by MicroPort Robotics, with significant gains in various healthcare stocks, indicating a positive market sentiment towards innovative drugs and healthcare technology [1] Group 1: Market Performance - The Hong Kong pharmaceutical sector saw a strong rally, with MicroPort Robotics leading the gains [1] - Other notable performers included JD Health, WuXi AppTec, Kingstar Bio, and Crystal International, with the CXO + AI healthcare-focused Hong Kong Stock Connect Medical ETF (520510) rising over 2% [1] - The Hang Seng Medical ETF (159892), which focuses on innovative drugs, increased by more than 1.5% [1] Group 2: Company Developments - MicroPort Robotics announced that its core product, the Tumi surgical robot, has accumulated over 100 commercial orders globally, with nearly 80 units installed, maintaining its position as the leading domestic brand [1] - The commercialization process for the Tumi robot is entering a phase of full acceleration [1] Group 3: Upcoming Events and Collaborations - The European Society for Medical Oncology (ESMO) annual meeting will take place from October 17 to 21 in Berlin, Germany, with a focus on business development (BD) collaborations among Chinese pharmaceutical companies [1] - Previous large transactions, such as the one between 3SBio and Pfizer, have validated the potential for domestic innovative drugs to enter international markets, positioning ESMO as a potential window for new authorizations [1] Group 4: Industry Outlook - Guotai Junan Securities believes that the upward trend in the innovative drug industry remains unchanged, with a historically dense period for global innovative drug product authorization collaborations occurring towards the end of the year [1] - The innovative drug sector is anticipated to see continued market activity driven by ongoing BD catalysts [1]

Core Insights - The 2025 European Society for Medical Oncology (ESMO) annual meeting is scheduled from October 17 to October 21 in Berlin, Germany, and is expected to showcase significant clinical research outcomes in oncology [1] - The focus of this year's ESMO is on innovative therapies and international presentations, with a notable increase in participation from Chinese pharmaceutical companies, featuring advanced pipelines such as PD-1 combination therapies and ADCs targeting prevalent cancers like non-small cell lung cancer and gastric cancer [1] - According to CICC, the business development (BD) collaborations of Chinese pharmaceutical companies around the meeting are worth monitoring, as previous large transactions, such as between 3SBio and Pfizer, have validated the potential for domestic innovative drugs to enter international markets [1] - The Hang Seng Pharmaceutical ETF (159892) has experienced a five-day adjustment following a previous surge, indicating that valuation concerns have been somewhat alleviated, and the upcoming ESMO meeting may lead to the announcement of significant data and BD transactions, potentially catalyzing the innovative drug sector [1] - In the upstream of innovative drugs, domestic CRO/CDMO companies are expected to maintain global competitiveness, as the trend of international division of labor and global pharmaceutical supply chains is unlikely to be reversed by short-term tariff policies [1] - The positive outlook for the innovative drug industry is anticipated to benefit CXO companies, with a focus on the CXO+AI medical sector, particularly the Hong Kong Stock Connect Medical ETF (520510) [1]

Core Insights - The stock price of InnoCare Pharma (映恩生物) reached a historical high of HKD 563.50 per share after being included in the Hang Seng Composite Index and successful Phase III clinical trial results for its core product DB-1303, but has since dropped to HKD 305 per share [2] - The Hong Kong innovative drug index surged from 666.91 to 1660.66 in the first nine months of the year, indicating a potential return to a bubble era for Chinese innovative drugs [2] - The founder and CEO, Zhu Zhongyuan, believes that industry development is akin to wine fermentation, where bubbles are a natural occurrence, and emphasizes that business development (BD) is a means to an end, not the goal [2][11] Company Overview - InnoCare Pharma, known as the "first ADC stock in China," has emerged as a strong player in the ADC (antibody-drug conjugate) sector, with 10 ADC clinical-stage pipelines [3] - The company went public on the Hong Kong Stock Exchange after a significant increase in stock price on its first day, raising the largest financing amount in the Hong Kong biotech sector [3] - The company’s lead product, DB-1303, has shown significant advantages over the established T-DM1 drug in clinical trials, and it is approaching the stage of market application [3][4] Clinical Development - DB-1303 is being developed for endometrial cancer, a condition with limited treatment options, and has received breakthrough therapy designation from both the FDA and CDE [3][4] - Another core product, DB-1311, targets B7-H3 and has entered global I/IIa clinical trials, with the company aiming to catch up with competitors in the ADC space [5][6] - InnoCare Pharma has initiated clinical trials in 20 countries, with over 2,700 patients enrolled, positioning itself among the leaders in the domestic biotech sector [6] Strategic Vision - Zhu Zhongyuan envisions a future where Chinese ADC companies will be globally recognized, focusing on the impact of their drugs on patient lives rather than merely on pipeline sales [7][12] - The company has established a "flywheel model" to leverage its experience in ADC development, aiming for partnerships with multinational pharmaceutical companies to secure funding and expand its network [8][9] - InnoCare Pharma has successfully completed multiple BD transactions with notable partners, including BioNTech and GSK, which has positioned it as a leading player in the domestic biotech landscape [9][10] Market Dynamics - The innovative drug market in Hong Kong has seen significant investment from multinational companies, with over 52.5% of global BD transactions related to Chinese innovative drugs as of August 2023 [10] - The stock price fluctuations in the biotech sector are influenced by market sentiment towards BD activities, with a notable correlation between overseas market rights and stock performance [11] - Despite current losses, the company is optimistic about its future, projecting significant milestone payments from existing BD agreements over the next two years [11][13]

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于沪深300指数5%以上) [28] Core Insights - From January to August 2025, the overall medical insurance fund income maintained positive growth, with total income reaching 18809.94 billion yuan, a year-on-year increase of 6.91%. Total expenditure was 15432.20 billion yuan, a year-on-year decrease of 1.80%. The cumulative surplus for the same period was 3377.74 billion yuan, a year-on-year increase of 79.74% [2][3][13] - The surplus rate for January to August 2025 was 17.96%, an increase of 7.28 percentage points compared to the same period in 2024. The surplus rate for August 2025 was 11.62% [2][13][15] - The medical insurance fund's performance improved compared to 2024, with only May showing a deficit in monthly surplus [13] Summary by Sections Medical Insurance Fund Performance - The medical insurance fund income from January to August 2025 was 18809.94 billion yuan, with a year-on-year growth of 6.91%. Expenditure was 15432.20 billion yuan, down 1.80% year-on-year. The cumulative surplus was 3377.74 billion yuan, up 79.74% year-on-year [2][6][13] - The surplus rate for the same period was 17.96%, which is an improvement from the previous year [2][13] Employee and Resident Medical Insurance - Employee medical insurance income for January to August 2025 was 11954.62 billion yuan, a year-on-year increase of 5.43%. In August, the income was 1452.27 billion yuan, up 1.97% year-on-year. Expenditure for the same period was 8811.88 billion yuan, a year-on-year increase of 2.24% [3][21] - For residents, the income was 6855.32 billion yuan, a year-on-year increase of 9.59%, while expenditure decreased by 6.70% [21][26] Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with rich pipelines, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group. It also highlights companies with significant single-product potential and those leading in advanced technology platforms [4][26] - In the CXO sector, companies like WuXi AppTec and Kelun Pharmaceutical are recommended, along with medical device companies that have been undervalued due to previous price pressures [4][26]

Core Viewpoint - Hong Kong Exchanges and Clearing Limited (HKEX) plans to launch the Hang Seng Biotechnology Index Futures on November 28, 2025, providing effective risk management tools for the rapidly growing biotechnology sector [2][3][4]. Group 1: Product Details - The new futures contract will have the code HBI, with a contract multiplier of HKD 50 per index point, and will be available for trading in the current month, the next three months, and the following three quarterly months [3]. - The first six months of trading will be exempt from the Securities and Futures Commission transaction fees, with the margin rate to be announced later [3][4]. Group 2: Market Context - The biotechnology sector is currently one of the hottest and fastest-growing industries in the Hong Kong capital market, driven by technological innovation and global healthcare demand [4]. - The Hang Seng Biotechnology Index has recorded a 63.61% increase over the past year, significantly outperforming the Hang Seng Index, which rose by 20.62% [4]. - Year-to-date, the Hang Seng Biotechnology Index has surged by 90.33%, surpassing the Hang Seng Technology Index's increase of 37.54% [4]. Group 3: Major Constituents - The index tracks the 30 largest biotechnology, pharmaceutical, and medical device companies listed on the Hong Kong Stock Exchange, with major constituents including WuXi Biologics, BeiGene, and Innovent Biologics [4][5]. - The top ten weighted stocks in the index include: - WuXi Biologics (10.83% weight, market cap HKD 120.825 billion) - BeiGene (10.21% weight) - Innovent Biologics (9.18% weight, market cap HKD 139.0 billion) - And others, contributing to a diverse representation of the sector [5]. Group 4: Industry Growth - Since the listing reforms in 2018, the biotechnology and healthcare sectors have become the fastest-growing industries in Hong Kong, with over 260 companies listed and a total market capitalization exceeding HKD 4.8 trillion, quadrupling from approximately HKD 1.2 trillion at the end of 2018 [6].

Core Viewpoint - The pharmaceutical sector, particularly innovative drugs, is experiencing significant volatility, with both A-shares and Hong Kong stocks showing sharp declines in recent trading sessions, indicating potential investment opportunities amidst market fluctuations [1][3][5]. Group 1: A-Share Market Performance - A-share market saw major declines in innovative drug stocks, with Beida Pharmaceutical dropping by 10.63%, Hengrui Medicine down 4.05%, and Baili Tianheng falling 6.18%, leading to a 2.21% drop in the only drug ETF (562050) [1]. - The CXO sector also faced declines, with WuXi AppTec falling 3.82%, while the largest medical ETF (512170) only decreased by 1.32%, indicating some resilience in the market [1]. Group 2: Hong Kong Market Performance - The Hong Kong pharmaceutical market experienced even more volatility, with innovative drug stocks like Kelun-Bio dropping 9.82% and major players like CSPC Pharmaceutical and Innovent Biologics falling over 6% [3]. - The Hong Kong Stock Connect innovative drug ETF (520880) opened up 1.86% but ended the day down 4.22%, marking its largest single-day drop since inception, with a trading volume of 4.1 billion [3]. Group 3: Investment Sentiment and Opportunities - Despite the ongoing market downturn, there is a noticeable increase in buying interest, as evidenced by a significant inflow of capital into the medical ETFs, suggesting that investors may be looking for "golden pit" opportunities in the pharmaceutical sector [5][6]. - Analysts suggest that the recent declines may be a release of short-term risks and emotional volatility, with potential for greater opportunities than risks if the market undergoes significant adjustments [5]. Group 4: Market Dynamics and Future Outlook - The fund manager of the Hong Kong Stock Connect innovative drug ETF highlighted the interconnectedness of the US and Chinese biopharmaceutical industries, suggesting that recent tariff tensions may lead to a "TACO trade" strategy, where investors anticipate a reversal of aggressive policies [6]. - The innovative drug sector is supported by strong fundamentals, including innovation capabilities and global competitiveness, which remain unchanged despite market fluctuations [6]. - With the global liquidity easing cycle initiated by the Federal Reserve, many institutions view Hong Kong stocks as undervalued and a favorable investment opportunity [7].